220 related articles for article (PubMed ID: 21151101)
21. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
Gavioli R; Vertuani S; Masucci MG
Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
[TBL] [Abstract][Full Text] [Related]
22. Differential splicing of antigen-encoding RNA reduces endogenous epitope presentation that regulates the expansion and cytotoxicity of T cells.
Kienzle N; Buck M; Silins SL; Burrows SR; Moss DJ; Winterhalter A; Brooks A; Khanna R
J Immunol; 2000 Aug; 165(4):1840-6. PubMed ID: 10925262
[TBL] [Abstract][Full Text] [Related]
23. Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells.
Sun Y; Sijts AJ; Song M; Janek K; Nussbaum AK; Kral S; Schirle M; Stevanovic S; Paschen A; Schild H; Kloetzel PM; Schadendorf D
Cancer Res; 2002 May; 62(10):2875-82. PubMed ID: 12019167
[TBL] [Abstract][Full Text] [Related]
24. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL
J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411
[TBL] [Abstract][Full Text] [Related]
25. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy.
Ozaki Y; Kontani K; Teramoto K; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Asai T; Ohkubo I
Biochem Biophys Res Commun; 2004 May; 317(4):1089-95. PubMed ID: 15094380
[TBL] [Abstract][Full Text] [Related]
26. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
27. Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.
Marescotti D; Destro F; Baldisserotto A; Marastoni M; Coppotelli G; Masucci M; Gavioli R
Immunology; 2010 Mar; 129(3):386-95. PubMed ID: 19922423
[TBL] [Abstract][Full Text] [Related]
28. Production of an antigenic peptide by insulin-degrading enzyme.
Parmentier N; Stroobant V; Colau D; de Diesbach P; Morel S; Chapiro J; van Endert P; Van den Eynde BJ
Nat Immunol; 2010 May; 11(5):449-54. PubMed ID: 20364150
[TBL] [Abstract][Full Text] [Related]
29. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
[TBL] [Abstract][Full Text] [Related]
30. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.
Hoffmann TK; Nakano K; Elder EM; Dworacki G; Finkelstein SD; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2000 Nov; 165(10):5938-44. PubMed ID: 11067956
[TBL] [Abstract][Full Text] [Related]
31. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.
van Elsas A; van der Burg SH; van der Minne CE; Borghi M; Mourer JS; Melief CJ; Schrier PI
Eur J Immunol; 1996 Aug; 26(8):1683-9. PubMed ID: 8765006
[TBL] [Abstract][Full Text] [Related]
32. Presentation and binding affinity of equine infectious anemia virus CTL envelope and matrix protein epitopes by an expressed equine classical MHC class I molecule.
McGuire TC; Leib SR; Mealey RH; Fraser DG; Prieur DJ
J Immunol; 2003 Aug; 171(4):1984-93. PubMed ID: 12902502
[TBL] [Abstract][Full Text] [Related]
33. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
[TBL] [Abstract][Full Text] [Related]
34. Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4.
Shingler WH; Chikoti P; Kingsman SM; Harrop R
Int Immunol; 2008 Aug; 20(8):1057-66. PubMed ID: 18567615
[TBL] [Abstract][Full Text] [Related]
35. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome.
Schultz ES; Chapiro J; Lurquin C; Claverol S; Burlet-Schiltz O; Warnier G; Russo V; Morel S; Lévy F; Boon T; Van den Eynde BJ; van der Bruggen P
J Exp Med; 2002 Feb; 195(4):391-9. PubMed ID: 11854353
[TBL] [Abstract][Full Text] [Related]
36. Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL.
Rubio-Godoy V; Dutoit V; Zhao Y; Simon R; Guillaume P; Houghten R; Romero P; Cerottini JC; Pinilla C; Valmori D
J Immunol; 2002 Nov; 169(10):5696-707. PubMed ID: 12421949
[TBL] [Abstract][Full Text] [Related]
37. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
[TBL] [Abstract][Full Text] [Related]
38. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells.
Kawashima I; Tsai V; Southwood S; Takesako K; Celis E; Sette A
Int J Cancer; 1998 Nov; 78(4):518-24. PubMed ID: 9797143
[TBL] [Abstract][Full Text] [Related]
39. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients.
Palmowski M; Salio M; Dunbar RP; Cerundolo V
Immunol Rev; 2002 Oct; 188():155-63. PubMed ID: 12445289
[TBL] [Abstract][Full Text] [Related]
40. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes.
Nelson D; Bundell C; Robinson B
J Immunol; 2000 Dec; 165(11):6123-32. PubMed ID: 11086045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
